DNase-seq adapts traditional DNase I footprinting 1 and leverages modern DNA sequencing to identify regions of the genome where regulatory factors interact with DNA to modify chromatin structure and ...
Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more ...
Mapping DNase I hypersensitive sites is an accurate method of identifying the location of gene regulatory elements, including promoters, enhancers, silencers and locus control regions. Although ...
Coronaviruses are a group of RNA viruses that cause diseases in mammals and birds. In humans and birds, they cause respiratory tract infections that can range from mild to lethal. Mild illnesses in ...
More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve ...
New research has developed an immunotherapy for cancer by combining DNase I with CAR T-cell therapy. The research conducted by Xenetic Biosciences titled, "The synergistic action of DNase I and CAR T ...
Xenetic (XBIO) Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I with chimeric antigen receptor T cells in a syngeneic ...
Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal ...
Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision ...
FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology ...
Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results